NCT04430699 2026-03-19Cisplatin+Pembrolizumab+RT in Vulvar CancerMassachusetts General HospitalPhase 2 Active not recruiting24 enrolled
NCT02628067 2025-09-22KEYNOTE 158Merck Sharp & Dohme LLCPhase 2 Active not recruiting1,609 enrolled 9 FDA